Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lung Neoplasms 3Esophageal Neoplasms 3Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Small Cell Lung Cancer Metastatic 1Neoplasm Metastasis 1Meningeal Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Brain Neoplasms 1

Interventions

Gemcitabine 33Cisplatin 22pembrolizumab 21Magnetic Resonance Spectroscopy 18Specimen Handling 16durvalumab 12Mitomycin 10enfortumab vedotin 9avelumab 9Nivolumab 9Cystoscopy 9Fluorouracil 8Carboplatin 8Radiation 7Cystectomy 7Radiotherapy 6Immunoglobulin G 6Docetaxel 6Disulfides 6atezolizumab 5Transurethral Resection of Bladder 5Mitozytrex 5Biopsy 5tremelimumab 4sacituzumab govitecan 4erdafitinib 4dehydroftorafur 4Standard of Care 4Platinum 41,2-diaminocyclohexaneplatinum II citrate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × patritumab deruxtecan × 90 days × Clear all
NCT06172478 2026-05-15

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Daiichi Sankyo

Phase 2 Recruiting
740 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡